The double-digit increase in the sales of the multiple myeloma drug Revlimid of Celgene Corp. contributed to its 37% leap in quarterly profits. Celgene, a biotechnology company based in the U.S. said that it is confident that its recently acquired treatment for Crohn’s disease will help maintain its profitability. According to the RBC Capital Markets […]
Home » Celgene